Colistin and doripenem combinations against Pseudomonas aeruginosa: Profiling the time course of synergistic killing and prevention of resistance

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1434-1442

  Ly, Neang S ^a   Bulitta, Jürgen B ^a,b   Rao, Gauri G ^a   Landersdorfer, Cornelia B ^a,b   Holden, Patricia N ^a   Forrest, Alan ^a   Bergen, Phillip J ^b   Nation, Roger L ^b   Li, Jian ^b   Tsuji, Brian T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Combination therapy; P. aeruginosa; Pharmacodynamics; Pharmacokinetics; Polymyxin

Indexed keywords

COLISTIN; DORIPENEM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; DRUG DOSE REGIMEN; ERADICATION THERAPY; HUMAN; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PSEUDOMONAS INFECTION; STEADY STATE; DRUG EFFECTS; DRUG POTENTIATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; THEORETICAL MODEL; TIME FACTOR;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, THEORETICAL; PSEUDOMONAS AERUGINOSA; TIME FACTORS;

EID: 84929734804     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku567     Document Type: Article

References (32)

1. Walker B, Barrett S, Polasky S et al. Environment. Looming global-scale failures and missing institutions. Science 2009; 325: 1345-6.
2. Boucher HW, Talbot GH, Benjamin DK Jr et al. 10×'20 Progress- development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:1685-94.
3. Li J, Nation RL, Milne RW et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25.
4. Bergen PJ, Bulitta JB, Forrest A et al. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 2010; 54: 3783-9.
5. Johansen HK, Moskowitz SM, Ciofu O et al. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 2008; 7: 391-7.
6. Bergen PJ, Forrest A, Bulitta JB et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 2011; 55:5134-42.
7. Bergen PJ, Tsuji BT, Bulitta JB et al. Synergistic killing of multidrugresistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011; 55: 5685-95.
8. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients froma multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
9. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430-6.
10. Deryke CA, Crawford AJ, Uddin N et al. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54: 4503-5.
11. Kwon JA, Lee JE, Huh W et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010; 35: 473-7.
12. Zusman O, Avni T, Leibovici L et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 2013; 57: 5104-11.
13. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
14. Bulitta JB, Yang JC, Yohonn L et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 2010; 54: 2051-62.
15. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
16. Drusano GL, Liu W, Brown DL et al. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J Infect Dis 2009; 199: 219-26.
17. Tsuji BT, Brown T, Parasrampuria R et al. Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56: 3712-9.
18. Matthews SJ, Lancaster JW. Doripenem monohydrate, a broadspectrum carbapenem antibiotic. Clin Ther 2009; 31: 42-63.
19. Howden BP, McEvoy CR, Allen DL et al. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 2011; 7:e1002359.
20. Bulitta JB, Ly NS, Yang JC et al. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 46-56.
21. Landersdorfer CB, Ly NS, Xu H et al. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother 2013; 57:2343-51.
22. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009; 49: 291-8.
23. Davies TA, Shang W, Bush K et al. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 1510-2.
24. Bulitta JB, Landersdorfer CB. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J 2011; 13:212-26.
25. Landman D, Georgescu C, Martin DA et al. Polymyxins revisited. Clin Microbiol Rev 2008; 21: 449-65.
26. Zavascki AP, Goldani LZ, Li J et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007; 60: 1206-15.
27. Ly NS, Yang J, Bulitta JB et al. Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012; 56:3453-6.
28. Tam VH, Schilling AN, Vo G et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 3624-30.
29. Macfarlane EL, Kwasnicka A, Ochs MM et al. PhoP-PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance. Mol Microbiol 1999; 34: 305-16.
30. McPhee JB, Lewenza S, Hancock RE. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol 2003; 50: 205-17.
31. Fernandez L, Gooderham WJ, Bains M et al. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS. Antimicrob Agents Chemother 2010; 54: 3372-82.
32. Perfeito L, Fernandes L, Mota C et al. Adaptive mutations in bacteria:high rate and small effects. Science 2007; 317: 813-5.